In different subgroups of antiviral therapy, the AUC of AFP in discriminating early-stage HCC was significantly higher in patients with ALT ≤ 1× ULN compared to patients with ALT > 1× ULN (0.796 vs. 0.682, p < 0.01) and as well as for patients with AST ≤ 1× ULN compared to patients with AST > 1× ULN (0.806 vs. 0.711, p < 0.01). This evidence concerns the gene GPT and hepatocellular carcinoma.